POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Sitemap
Triplets with
POMALYST
- POMALYST + dex + dara
- Trial Design
- Efficacy
- Safety
- POMALYST + dex +
EMPLICITI® (elotuzumab) - Trial Design
- Efficacy
- Safety
- POMALYST + dex + isa
- Trial Design
- Efficacy
- Safety
Information about POMALYST + dex + daratumamab (dara) and POMALYST + dex + isatuximab (isa) does not appear in the POMALYST full Prescribing Information. Please see the dara and isa full Prescribing Information for a discussion of Important Safety Information at
www.darzalex.com (dara) and www.sarclisa.com (isa).